Clinical trials
Advanced or Metastatic Breast Cancer clinical trials
Below are recruiting advanced or metastatic breast cancer clinical trials, each written for real people, not researchers. We’re tracking 6,090 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07754409Recruiting
Quality of life during lung cancer treatment with immunotherapy
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
GothenburgAges 18 years+ - NCT07755397RecruitingPhase 1
Study of JBI-778 for lung, brain, and salivary gland tumors
This trial tests a new oral medication, JBI-778, in patients with certain types of lung cancer, brain tumors, or salivary gland cancer. The drug is designed to target specific genetic changes in these tumors, and the study aims to assess its safety and effectiveness.
Surat, GujaratAges 18 years+ - NCT07752953Recruiting
Personalized immune cell therapy for solid tumors
This trial tests a personalized cancer vaccine made from your own immune cells to help your body fight the tumor. It is for people with solid tumors that have not responded to other treatments.
Qinhuangdao, HebeiAges 18–75 - NCT06587425RecruitingPhase 2
Combination therapy for CLDN18.2-positive advanced stomach cancer
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06603376RecruitingPhase 2
Drug combo for BRAF-mutated advanced colorectal cancer
This trial tests a combination of four drugs (irinotecan liposome, fluorouracil, folinic acid, vermofenib, and cetuximab) as a first treatment for people with advanced colorectal cancer that has a specific BRAF V600E mutation. It aims to see if this combination can shrink tumors or slow their growth.
ShanghaiAges 18–80 - NCT05014464RecruitingPhase 2
Testing ALK-targeted pills for ALK-positive advanced squamous cancer
This Phase 2 study tests whether ALK-targeted drugs can shrink or control advanced squamous cell cancer that has spread. You may be eligible if your tumor has an ALK gene rearrangement and you have not had prior cancer medicines for this stage.
Changsha, HunanAges 18 years+ - NCT06355609RecruitingPhase 2
Targeted therapy for advanced EGFR-mutant lung cancer
This trial tests a combination of two targeted pills (sunvozertinib and anlotinib) as a first treatment for people with advanced lung cancer that has a specific EGFR mutation. It aims to see if this combination works better than current standard treatments.
Changsha, HunanAges 18 years+ - NCT07744152RecruitingPhase 1
Testing a new drug for advanced solid tumours
This study tests a new drug called BI 3822971 for people with advanced cancer that has not responded to standard treatments. The goal is to find the best dose that is safe and well-tolerated.
LeuvenAges 18 years+ - NCT07746713RecruitingPhase 1
Study of a new drug for advanced prostate cancer that has spread and progressed
This study tests a new drug called JNJ-98768111 in people with advanced prostate cancer that has spread and is no longer responding to current hormone-based treatments. It aims to see if the drug is safe and effective, and participants will receive the study drug while continuing some standard hormone therapy.
Sarasota, FloridaAges 18 years+ - NCT05495152RecruitingPhase 3
Sintilimab after esophageal surgery to help prevent cancer return
This trial looks at adding sintilimab (an immunotherapy) after surgery for certain stages of esophageal squamous cell cancer. The goal is to lower the chance the cancer comes back after standard treatment.
Zhengzhou, HenanAges 18–70 - NCT07730021RecruitingPhase 1/Phase 2
New drug for advanced solid tumors
This trial tests a new drug called ASP388B, given alone or with standard treatments, for people with certain advanced solid tumors that have stopped responding to therapy. It may help shrink tumors or slow their growth.
Lake Success, New YorkAges 18 years+ - NCT06627634Recruiting
Surgery for stomach cancer that spread to the liver
This trial tests if removing the stomach tumor and liver spots together can help people with stomach cancer that has spread only to the liver. It is for those who are healthy enough for surgery and chemotherapy.
Aarhus, JyllandAges 18 years+ - NCT07731828RecruitingPhase 2
Short-course radiation plus immunotherapy and chemo for cervical cancer
This trial tests a new combination of short-course radiation, an immunotherapy drug called adebrelimab, and standard chemotherapy before surgery for locally advanced cervical cancer. It aims to see if this approach can shrink tumors more effectively.
Nanjing, JiangsuAges 18–80 - NCT07717827Recruiting
Brain tumor surgery guided by brain wiring maps
This trial uses advanced brain scans to create a detailed map of your brain's wiring before surgery. This helps surgeons remove more tumor safely while protecting important areas that control movement, language, and vision.
Palermo, PAAges 18 years+ - NCT06637007RecruitingPhase 2
Chidamide plus AK112 for advanced sarcoma after first treatment
This trial tests two new drugs (chidamide and AK112) together for people with advanced bone or soft tissue sarcoma that has not responded to standard first-line treatment. The goal is to see if this combination can shrink tumors or slow their growth.
Taiyuan, ShanxiAges 18–75 - NCT02292641Recruiting
MRI study for repeat pelvic colorectal cancer
This study uses a special MRI to help understand and stage colorectal cancer that has come back in the pelvis. The goal is to improve how doctors make treatment decisions after previous surgery.
OsloAges 16 years+ - NCT07699939RecruitingPhase 2
Perioperative immunotherapy plus chemo for advanced gastric cancer
This trial tests whether adding the immunotherapy drug HLX10 (serplulimab) to standard chemotherapy (S-1 plus oxaliplatin) before and after surgery can improve outcomes for patients with advanced gastric or gastroesophageal junction cancer that has a high level of PD-L1 protein.
Chiba, ChibaAges 18–80 - NCT07704177RecruitingPhase 2
A study of trastuzumab rezetecan plus two other drugs for advanced bile duct cancer
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Beijing, Beijing MunicipalityAges 18–80 - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT05725265Recruiting
Low-level laser treatment for arm swelling after breast cancer
This study tests whether low-level laser therapy can safely reduce swelling in one arm caused by breast-cancer treatment. It compares the laser to a look-alike inactive (placebo) treatment and checks changes over time.
TaipeiAges 20 years+ - NCT06614790Recruiting
Niraparib maintenance for advanced ovarian cancer
This study looks at how well the drug niraparib works as a maintenance treatment for women with advanced ovarian cancer that responded well to initial platinum-based chemotherapy. It may help keep the cancer from coming back.
BialystokAges 18 years+ - NCT07678970RecruitingPhase 1
Study of SI-B036 for advanced gastrointestinal and other solid tumors
This trial tests a new drug called SI-B036 in people with advanced digestive tract or other solid tumors that have spread. It aims to see if the drug is safe and effective. You may qualify if you have a measurable tumor and are in relatively good health.
Harbin, HeilongjiangAges 18–75 - NCT07678593RecruitingPhase 1/Phase 2
Study of a new drug combined with standard therapy for RAS-mutated cancers
This study tests a new drug (GFH276) combined with either cetuximab or chemotherapy for people with advanced solid tumors or pancreatic cancer that have a specific genetic change (RAS mutation). The goal is to see if this combination can shrink tumors or slow their growth.
Concord, New South WalesAges 18 years+ - NCT07674732RecruitingPhase 2
Shorter radiation with immunotherapy for rectal cancer
This trial tests a shorter course of radiation followed by a combination of chemotherapy, immunotherapy, and a targeted drug (bevacizumab) for locally advanced rectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS). The goal is to see if this approach can shrink the tumor enough for surgery while avoiding more extensive radiation.
Guangzhou, GuangdongAges 18–75
Hear when a new Advanced or Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic breast cancer?
- Yes. Clin2 currently lists 6,090 recruiting advanced or metastatic breast cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic breast cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic breast cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.